Yichen Li

Yichen Li

Auto-generated profile, based on publicly available information

Yichen Li

Cleveland Clinic Genome Center, Cleveland Clinic Research, Cleveland Clinic, Cleveland, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2026 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
YHYuan Hou
Yuan Hou
YLYichen Li
Yichen Li
PZPengyue Zhang
Pengyue Zhang
NLNoah Lorincz-Comi
Noah Lorincz-Comi
DGDhruv Gohel
Dhruv Gohel
FCFeixiong Cheng
Feixiong Cheng
Despite prolific genomic data from individuals with Alzheimer’s disease (AD), translation into treatments has lagged. Here we applied Mendelian randomization to multiple AD genome-wide association studies and functional multiomics datasets to nominate druggable targets, identifying 19 targets for individuals of European ancestry and 7 for African ancestry. This included epoxide hydrolase 2 (EPHX2), for which we identified a protective missense variant (p.Arg287Gln). Experiments in induced pluripotent stem cell-derived neurons and cerebral organoids from patients with AD validated the protective role of p.Arg287Gln via reduced levels of EPHX2 and phosphorylated tau (pTau-181). Pharmacological inhibition of EPHX2 improved cognitive performance in the 5xFAD mouse model of AD. Finally, by leveraging electronic health data from 111,680 patients with mild cognitive impairment, we identified 12 drugs associated with reduced AD incidence, including trazodone (targeting ADRA1A) and baclofen (targeting GABBR1). Thus, integrating multiomics data, functional validation and electronic health data identifies new approaches for treating AD.

26 February 2026 in Research Square
Verified
Preprint
Open access
PDF file
FCFeixiong Cheng
Feixiong Cheng
YRYunxiao Ren
Yunxiao Ren
MPMaria Paz
Maria Paz
XYXiaoyu Yang
Xiaoyu Yang
YLYichen Li
Yichen Li
APAndrew Pieper
Andrew Pieper
Although genetic variants are among the strongest risk factors for Alzheimer’s disease (AD), most associated variants reside in non-coding regions with unclear mechanisms. Here, we address that gap by fine-tuning the Akita DNA foundation model on high-resolution Hi-C data generated from neuronal progenitor cells (NPCs) and microglia to produce iNeuroAkita , a cell-context-aware three-dimensional (3D) genome model. iNeuroAkita shows improved correlation with experimental Hi-C contact maps and more accurate contact predictions at key AD loci (e.g. APOE and PSEN2) , and captures CTCF-dependent chromatin loops. Using in silico saturation mutagenesis (ISM) across 11,856 AD-associated single-nucleotide variants (SNVs) and 120 structural variants (SVs), we quantified impacts on chromatin spatial organization and identified two SNVs predicted to strongly disrupt 3D chromatin architecture: rs636317 at the MS4A locus that is predicted to disrupt local chromatic interactions and microglia eQTL rs7599054 that creates gained interactions connecting its surrounding region to CCNT2 and TMEM163 , consistent with enhancer–promoter activation in epigenomic and single-cell transcriptomic data. We also identified AD-associated deletions at the KANSL1 and ARMS2 that rewire local regulatory contacts and associate with cell-type-specific expression changes, demonstrating iNeuroAkita’s utility for systematic characterization of noncoding AD risk variants underlying 3D genome regulation.